ABEO Earnings Preview: Options Price a ±126.8% Move

· The NYC Memo · ABEO reports 2026-11-11

Abeona Therapeutics Inc. reports November 11, 2026. The March 19, 2027 straddle implies ±126.83% against a 6.68% average reaction, with dealers long gamma and max pain at $5.

Live updates

Nov 11 — Ahead of ABEO earnings on November 11, 2026, the implied move expanded from ±19.69% to ±126.83% as at-the-money implied volatility rose from 84.6% to 293.7%, implying that options pricing reflects expectations of a significantly wider post-announcement price swing.

Nov 10 — Heading into November 11, 2026 earnings, ABEO dropped from $4.17 to $2.54 while its implied move narrowed from ±28.78% to ±19.69% and implied volatility fell from 183.9% to 84.6%, indicating that the market anticipates a smaller post-earnings price reaction.

Abeona Therapeutics Inc. reports on November 11, 2026, with ABEO spot at $2.46. The stock is -49.9% over the past month and sits -67.9% from its 52-week high. For the March 19, 2027 expiry, the straddle costs $3.12 with atm iv at 293.7%. This establishes an implied move of 126.83% inside an implied range of $-0.66 to $5.58. Across 7 prints counted, the average realised reaction is 6.68%, with 3 higher and 4 lower.

Dealer positioning currently indicates a dealer lean of long gamma, which typically cushions the tape and limits volatility into the upcoming announcement. Open interest features a put_call_oi of 0.66, alongside a max pain mark at $5.

What the market will be watching

The options desk will focus on commercial progress and pipeline execution for Abeona Therapeutics. Traders will watch patient demand and product uptake following regulatory developments. Operating expenses remain central to the print, especially manufacturing buildout costs and clinical trial outlays that pressure margins. The market expects updated guidance covering operational spending and commercialization timelines for the remainder of the year. The desk will trade any management commentary regarding regulatory interactions, launch preparations, and the current liquidity runway.

What the options market is pricing

MeasureLevel
PrintNovember 11, 2026
Expiry usedMarch 19, 2027 (128 days out)
Spot$2.46
ATM straddle$3.12
Implied move±126.83% ($-0.66 to $5.58)
ATM implied vol293.7%
Put/call open interest0.66
Max pain$5
Net dealer gamma+$0.00mn per 1% move, LONG GAMMA
Heaviest call strike above spot$4 (424 contracts)

Dealers sit long gamma into the print, which means their hedging leans against the move and tends to compress ABEO between catalysts. That damping disappears the moment the number crosses the tape.

How the stock has reacted before

ReportNext-day move
Q2 2026, Aug 13-14.95%
Q1 2026, May 13+0.53%
Q4 2025, Mar 17-3.84%
Q3 2025, Nov 12+18.47%
Q1 2025, Jul 2+5.39%
Q4 2024, Mar 20-1.15%
Q3 2024, Nov 14-2.46%

Across the last 7 prints the average absolute reaction is 6.68%, with 3 higher and 4 lower. The best was +18.47% and the worst -14.95%. Options are asking ±126.83%, which is 120.15 points richer than the realised average, the premium seller's case.

Where the stock is trading

MeasureLevel
Spot$2.46
52-week range$2.30 to $7.65
Position in that range3%
From the 52-week high-67.9%
From the 52-week low+6.7%
Past week-42.2%
Past month-49.9%
Past three months-67.1%
50-day average$4.92
200-day average$5.44

How the options market is pricing it

The March 19, 2027 straddle marks $-0.66 to $5.58 as the range the options market is paying for into the print, with ATM implied vol at 294% set to drain the morning after. A reaction inside that band hands the edge to premium sellers; a break outside it rewards premium buyers. Historically ABEO has moved 6.68% on earnings against the ±126.83% now implied, so the market is pricing this print richer than the recent average. Which side of that trade is right depends on the number, the guidance and where positioning unwinds.

Read the mechanics behind the crush in our earnings volatility guide, and pull the live memo for ABEO before the print.

Data as of November 11, 2026 from the live option chain, exchange price history and SEC-dated earnings reactions. This is research, not investment advice.

Related: ABEO options memo

More earnings previews